Premium
Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV‐associated Hodgkin's disease
Author(s) -
Makinson Alain,
Martelli Nicolas,
Peyrière Hélène,
Turriere Chrystell,
Moing Vincent Le,
Reynes Jacques
Publication year - 2007
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2007.00827.x
Subject(s) - vinblastine , abvd , dacarbazine , lopinavir , medicine , ritonavir , neutropenia , chemotherapy , lymphoma , oncology , virology , gastroenterology , human immunodeficiency virus (hiv) , vincristine , antiretroviral therapy , viral load , cyclophosphamide
A HIV infected patient was treated for stage IVB Hodgkin's lymphoma by ABVD (doxorubicine, bleomycine, vinblastine, dacarbazine) chemotherapy and lopinavir–ritonavir based antiretroviral therapy inducing profound life‐threatening neutropenia. Vinblastine and lopinavir–ritonavir interaction was managed with lopinavir–ritonavir interruption around chemotherapy administration, with complete remission and immunovirological success after six cycles. This unrecorded strategy is discussed.